Bayer | Pharmaceuticals

#NEWS: We will be presenting new data from our Phase III program at the upcoming International Society of Gynecological Endocrinology (ISGE) Congress from March 4-6 in Rome. #WomensHealth #TeamBayer #HealthForAll #HungerForNone

#News: Bayer has received a significant approval in China, providing a new treatment option for men with advanced prostate cancer. This approval is based on positive clinical data & allows physicians to better tailor therapy plans to meet the individual needs of patients.

#News: Bayer has received a positive CHMP opinion for its potential new treatment option for heart failure patients with LVEF ≥40% in the EU. This is a crucial step towards approval for a patient group currently facing limited treatment options and high cardiovascular risk.

#NEWS: Together with @BlueRockTx, we’ve achieved an important step: U.S. FDA has granted Orphan Drug Designation for our investigational cell therapy to treat retinitis pigmentosa. Learn more: bayer.com/media/en-us/

#NEWS: Bayer starts Phase III study (with a levonorgestrel-releasing intrauterine system) for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.

#News: Bayer is proud to be attending the 33rd @cogicongress 🎉 We look forward to connecting with global experts and exploring new advances in women’s health.

+++ Exciting #news ++ Bayer announces positive topline results from the international Phase III study. #TeamBayer #HealthForAll #HungerForNone

#News: Bayer will be contributing to the conversation at The Menopause Society’s (@MenopauseOrg) 2025 Annual Meeting, where experts will share the latest research and advancements shaping the future of menopause care. #MenopauseSocietyMtg

@dilucatoni Thanks for letting us know! We’ve flagged this internally and appreciate you bringing it to our attention.

@BayerPharma Aquí os dejo un anuncio que lleva un tiempo circulando por Facebook España y que puede ser peligroso para los enfermos de azúcar en sangre. Y perjudicial para vuestra marca.

#NEWS: #TeamBayer is pleased to share that the Chinese authorities have accepted our new drug application for our low dose #MRI contrast agent. Learn more: bayer.com/en/media-overv…

#News: Bayer is presenting research at the World Sleep Congress 2025 in Singapore, focusing on sleep disturbances during menopause. Up to 60% of women experience these challenges. Join us in exploring solutions for this unmet medical need. Learn more: bayer.com/media/en-us/

New data highlighting advancements in retinal health will be presented at this year's EURETINA conference. Learn more: spr.ly/6047NJ0xW

#NEWS: #TeamBayer is pleased to share that the US Food and Drug Administration (FDA) has accepted our new drug application for our low dose hashtag#MRI contrast agent. Find out more: bayer.com/en/media-overv…

#NEWS: China Accepts Bayer's NDA for investigational oncologic therapy in HER2-Mutant Lung Cancer.

@stottiecake70 Thank you for trusting Rennie! To help you find local availability, could you please share your country? We’ll connect you with our Consumer Health team for tailored support. We appreciate your patience!

@BayerPharma Do you know when you'll have reliable stocks of Rennie orange indigestion chewable tablets? as I must use them to digest fibre it's getting harder to obtain them

#NEWS: The FDA has approved a new therapy for adult patients living with a common type of heart failure. Learn more: spr.ly/60164NuAI

#TeamBayer, along with @BlueRockTx, shares that the first patient has been enrolled in a Phase 1/2a clinical trial of an investigational cell therapy targeting primary photoreceptor diseases. This approach could potentially restore vision for patients: bayer.com/media/en-us/

@RCObsGyn 2025 is underway and Bayer will present on menopause symptoms to further understanding of the menopausal transition. At Bayer, we are charting a path towards transforming women’s health for the better. #HealthForAll #HungerForNone

#TeamBayer announced the results of a Phase II study about simultaneous initiation of two treatments in patients with chronic kidney disease and type 2 diabetes. Data have also been published in the New England Journal of Medicine. Learn more: bayer.com/media/

#TeamBayer, together with @VividionRx, is advancing a clinical-stage WRN inhibitor for MSI-high cancers. This innovative approach aims to target cancer cells while minimizing harm to healthy cells, potentially offering new treatment options for patients: bayer.com/media/